Format

Send to

Choose Destination
Therapie. 2019 Apr;74(2):279-288. doi: 10.1016/j.therap.2018.09.076. Epub 2019 Jan 31.

The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.

Author information

1
Service de pharmacologie médicale et clinique, laboratoire de pharmacologie médicale et clinique, faculté de médecine, université de Toulouse III, 37, allées Jules-Guesde, 31000 Toulouse, France; CIC 1436, service de pharmacologie médicale et clinique, CHU de Toulouse, 31000 Toulouse, France; UMR 1027 Inserm, université de Toulouse, 31000 Toulouse, France. Electronic address: cecile.conte@univ-tlse3.fr.
2
Département de chirurgie oncologique et gynécologique, CHU de Toulouse, 31000 Toulouse, France.
3
Inserm, UMR 1219, Bordeaux population health research center, team pharmacoepidemiology, université de Bordeaux, 33000 Bordeaux, France; Inserm CIC1401, Bordeaux PharmacoEpi, 33000 Bordeaux, France; Pôle de santé publique, service de pharmacologie médicale, CHU de Bordeaux, 33000 Bordeaux, France.
4
Service de pharmacologie médicale et clinique, laboratoire de pharmacologie médicale et clinique, faculté de médecine, université de Toulouse III, 37, allées Jules-Guesde, 31000 Toulouse, France; CIC 1436, service de pharmacologie médicale et clinique, CHU de Toulouse, 31000 Toulouse, France; UMR 1027 Inserm, université de Toulouse, 31000 Toulouse, France.

Abstract

Some concerns have emerged about the evidence of benefits on survival outcomes or quality of life of new anticancer drugs. In parallel, the decreased cancer mortality leads to an increased number of patients exposed to cancer treatment-related consequences. In this context, pharmacoepidemiology is crucial to assess anticancer drug use, effectiveness and safety in real life conditions. We aimed to describe strengths, limitations and considerations associated with the use of the French national health insurance database (système national des données de santé [SNDS]) to conduct pharmacoepidemiological studies in oncology. The SNDS represents a powerful tool in pharmacoepidemiology owing to its extensive coverage, accurate description and quantification of drug exposure and individual data on patients. The main limitations of this database ensue from the administrative nature resulting in technical difficulties in its management and gaps in availability of data. Another limitation is the lack of accurate identification of diseases, comorbidities or outcomes and potential confounding with notably the lack of data regarding cancer stage, prognosis or risk factors. Finally, the accurate identification of the nature of chemotherapy received by patients is sometimes complex. To minimize these limitations, several approaches and statistical methods could be used as highlighted by national or international initiatives. First, the SNDS may be linked with cancer registry or clinical data. Then, several data sources could be combined using meta-analytical methods. The development of methodological tools and the use of standardized methods are crucial to enhance the quality of studies that can impact clinical practice and guide public decision. Pharmacoepidemiological approaches and pharmacovigilance represent an important cornerstone in oncology for signal detection or long-term follow up of cancer patients. In this context, validated methods to identify cancer patients and to describe chemotherapy regimens within these data should be promoted and remain too scarce despite international guidelines. Moreover, limits and strength of each data sources should be systematically discussed according to the research question. Optimized and framed use of claims database represents a future challenge in onco-pharmacoepidemiology.

KEYWORDS:

Anticancer drugs; Benefit; Electronic claims databases; Electronic health care databases; Oncology; Pharmacoepidemiology; Safety; Utilization

PMID:
30824175
DOI:
10.1016/j.therap.2018.09.076
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center